Latest news with #eBioMedicine
Time of India
18 hours ago
- Health
- Time of India
Using non-stick cookware at home? Here's why it could increase the risk of type 2 diabetes
A recent study by Mount Sinai researchers reveals a significant link between exposure to PFAS, commonly known as forever chemicals, and an increased risk of developing type 2 diabetes. Analyzing data from over 70,000 participants, the study found that higher PFAS levels correlate with a 31% increase in diabetes risk, potentially due to metabolic irregularities. Forever chemicals are everywhere. From the water we drink to the food we eat, and even in human cells, this class of synthetic chemicals is everywhere. But can they cause illnesses? A recent study has looked at the association between forever chemicals and type 2 diabetes. A new study led by Mount Sinai researchers found a close link between forever chemicals and diabetes. The findings are published in eBioMedicine . What are forever chemicals Forever chemicals, which were developed in the 1940s, have become a part of our lives now. Also known as PFAs, per- and polyfluoroalkyl substances, forever chemicals, are a class of synthetic chemicals. Known for their durability (resistance to heat, oil, and water), PFAs are used in products ranging from Teflon pans to cosmetics, dental floss, and fast-food wrappers. Yes, from nonstick cookware to stain-resistant furniture to waterproof clothing, PFAs are everywhere PFAs and type 2 diabetes The researchers have now found a link between PFAs and type 2 diabetes. They found that exposure to these chemicals may increase the risk of developing type 2 diabetes. They found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. To understand the impact of PFAs on human health, the researchers conducted a study. They looked at the data of more than 70,000 study participants who have sought care at The Mount Sinai Hospital in New York City since 2007. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like If you have a mouse, play this game for 1 minute Navy Quest Undo by Taboola by Taboola Based on available data, the researchers analyzed 180 people recently diagnosed with type 2 diabetes (T2D) and compared them to 180 similar individuals without diabetes. The researchers then looked at their blood samples to analyze PFAS levels. They found that higher levels of PFAS were associated with a significantly greater risk of developing T2D in the future. Each increase in range of PFAS exposure was linked to a 31% increase in risk. They also found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. What are the experts saying Vishal Midya, PhD, MStat, corresponding author and assistant Professor, Environmental Medicine, Icahn School of Medicine at Mount Sinai, said, 'PFAS are synthetic chemicals that resist heat, oil, water, and stains, and are found in countless everyday consumer products. Because they don't break down easily, PFAS accumulate in the environment—and in human bodies. Our study is one of the first to examine how these chemicals may disrupt the body's metabolism in ways that increase diabetes risk—particularly in diverse US populations. ' Supreme Court Pushes Central Govt to Finalise FOPL: What It Means & Why It Matters? | Explained The study emphasizes the importance of preventing PFAS exposures to promote public health. 'This research leverages an exposomics framework to characterize environmental impacts and associated metabolic alterations contributing to the development of type 2 diabetes in vulnerable US populations. Findings can help us design more effective interventions for the early prevention of type 2 diabetes in the future, taking into account individuals' exposures to environmental chemicals along with other well-known genetic, clinical, and lifestyle factors implicated in diabetes development. Mounting research suggests that PFAS are a risk factor for several chronic diseases, such as obesity, liver disease, and diabetes,' Damaskini Valvi, MD, PhD, MPH, senior author and associate professor, Public Health and Environmental Medicine, Icahn School of Medicine at Mount Sinai, added.
Yahoo
4 days ago
- Health
- Yahoo
New test could revolutionise aftercare for thousands of breast cancer patients
Scientists have developed a new test for certain breast cancer patients which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. This is your breast check reminder! Learn the signs and symptoms of breast — Breast Cancer Now (@BreastCancerNow) May 6, 2025 They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
The Independent
4 days ago
- Health
- The Independent
Breast cancer breakthrough as new test could revolutionise treatment
A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
Daily Mail
4 days ago
- Health
- Daily Mail
New test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return
A new test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return. The breakthrough could spare thousands of patients unnecessary therapy while allowing others to receive more intensive care sooner. Researchers at The Institute of Cancer Research, London, found taking hormone drugs for a fortnight changed the characteristics of some tumours, causing them to shift their subtype. Patients with the highest risk of relapsing had a type of tumour called Luminal B that did not change after this short-term therapy. These cases, accounting for 6 per cent of the 213 patients studied, require more intensive treatment that others could avoid. Experts say the findings, published in the journal eBioMedicine, highlight the benefit of taking hormone therapy before surgery to help guide doctors' decision making. The new test works for a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive, of which there are around 200,000 cases globally each year. Study author Dr Maggie Cheang, from the ICR, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. 'In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of the IRC, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at charity Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
Medical News Today
15-07-2025
- Health
- Medical News Today
Eating late in the evening could make blood sugar control harder for the body
Our bodies process food differently depending on the time of day, with metabolism generally more active in the late eating is linked to obesity and heart disease, its exact effects on glucose metabolism and the role of genetics are still unclear.A new twin study from Germany now offers fresh insight into how meal timing interacts with our internal clocks and overall circadian system is a complex 24-hour timekeeping system that controls behaviour and metabolism through a central clock in the brain and additional clocks in organs such as the liver and of this system, our metabolism responds differently depending on when we eat, resulting in daily variations in glucose processing and hormone release after intake itself serves as an important signal that helps align our internal at times that are out of sync with the natural light-dark cycle, for example, when working night shifts, can disrupt these internal clocks and lead to adverse metabolic at the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have recently investigated the link between blood sugar metabolism and evening eating times using data from a twin study conducted in 2009– findings are published in the journal do we calculate circadian rhythms?Earlier research has shown that consuming meals late at night is linked to a higher risk of obesity and heart we still do not fully understand how meal timing interacts with a person's individual circadian rhythm and affects glucose metabolism and diabetes addition, the specific mechanisms behind when and why people eat remain unclear, as eating habits are shaped by a mix of cultural, situational, genetic and other biological timing of food intake in relation to a person's biological daily rhythm can be assessed by looking at the gap between mealtime and the midpoint of sleep midpoint refers to the time exactly halfway between falling asleep and waking up, and it indicates a person's chronotype, that is, whether they tend to be an early bird or a night late-night eating affects insulin sensitivityThe NUGAT study was carried out between 2009 and 2010 at the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE).To recruit participants, researchers used a twin registry (HealthTwiSt, Berlin, Germany) and public advertisements. In total, 92 individuals (46 pairs of identical and fraternal twins) took the twins completed two nutritional interventions during the study, these interventions were not relevant to the results discussed participants underwent comprehensive metabolic assessments, which included physical exams, medical history reviews, body measurements, and glucose tolerance tests. Their individual chronotypes were identified using a addition, each participant kept handwritten food diaries over 5 consecutive days (3 weekdays and 2 weekend days), recording the start and end times of each meal along with details on the type and quantity of food approach helped capture a realistic picture of their usual eating the analysis indicated that people who tended to have their final meal later in the day and closer to bedtime also had less effective glucose (blood sugar) metabolism at the end of the day, as they had lower insulin may suggest that better regulating our meal times may help maintain our metabolic you avoid eating late in the evening?Destini Moody, RD, CSSD, LD, registered dietitian at Top Nutrition Coaching, not involved in this research, reviewed the study and spoke to Medical News Today about its findings.'In general, I'm skeptical about adjusting the timing of one's eating in the hopes of controlling weight or blood sugar unless you are diabetic,' Moody told us.'My colleague and I used to joke that your digestive system doesn't work in shifts, meaning it doesn't 'clock out' after a certain time of day and decide to start storing everything as fat,' she added.'While it's well known that eating timing and meal composition is critical for controlling blood sugar and insulin action in those with diabetes, this study was performed on healthy individuals with normal pancreatic function and no other metabolic disturbances. Even without diabetes, those with metabolic syndrome should be careful about their level of insulin resistance, but none of the subjects fell under this category either given their BMI and waist circumference. The average age of subjects was also 32, which is relatively young.'– Destini Moody, RD, CSSD, LD'As far as the genetic component of how eating timing influences insulin sensitivity, this is a mixed bag, [too]' Moody further noted. 'On the one hand, it's an interesting finding, but on the other hand, genetic factors are difficult to detect and control.''In general, blood sugar variations are a natural part of digestion and metabolism, and I would urge the public to refrain from stressing about the effects food may have on their blood sugar unless they have metabolic ailments like type 2 diabetes,' she she did emphasize that it is always important to pay attention to how much fiber we ingest, and how much of it comes from refined explained:'Foods with added sugars, that have been made with refined grains, and are generally low in fiber will raise blood sugar quickly and send it crashing back down due to a rebound effect. This tends to make people even hungrier and even cause fatigue, which is why you feel sleepy after having meals high in these types of carbs. Luckily, eating whole grains and high fibers fruits and vegetables along with lean protein can not only help mitigate this effect, but often results in a healthier diet overall that helps prevent the risk of chronic disease.'
